FDA's ZYN ULTRA Orders: What It Judged Beyond the Label

On August 21, 2026, the FDA authorized the marketing of eleven new nicotine pouch products through the premarket tobacco product application (PMTA) pathway, all made by Swedish Match USA, Inc. and sold under the ZYN ULTRA brand (FDA). Ten carry a labeled strength of 9mg, and one, ZYN ULTRA Smooth, carries 11mg (FDA).

The product count is the least useful part of that announcement. Sitting in the middle of it is a short passage in which the agency explains how it decides what a nicotine pouch actually delivers, and it says something a nicotine buyer should read twice: the number printed on the can is not the measure.

For anyone specifying a nicotine ingredient, that reframes what a supplier has to be able to prove. If exposure is a function of design, formulation and materials rather than a labeled milligram figure, then the evidence behind an application lives in specification-level detail, and a good deal of that detail originates upstream.

What FDA Authorized on August 21

The FDA reviewed these applications under its nicotine pouch pilot program, and reports a running total of 43 nicotine pouch products authorized overall, 23 of them through the pilot (FDA). What the pilot means for anyone still preparing an application is a separate question, covered in our post on the pilot closing to new products.

One word in the announcement is worth guarding. These products are authorized, not approved. The FDA describes its action as authorizing the marketing of the products (FDA), and federal law makes it a prohibited act to state or imply to consumers, in a label or labeling or through the media or advertising, that a tobacco product is approved by the FDA (21 U.S.C. 331(tt)). It is worth keeping that distinction intact in technical and trade documentation, where loose wording tends to get copied forward.

The regulatory text quoted throughout this post is 21 CFR Part 1114 as in force on August 25, 2026 (21 CFR 1114.7), and the authorization details are as the agency published them on August 21, 2026 (FDA).

Labeled Nicotine Content Is Not the Measure

Here is the passage that matters, in the agency's own words. In reviewing nicotine pouch applications, the FDA states that nicotine exposure "is influenced not only by a product's labeled nicotine content, but also by its design, formulation, materials, and other characteristics that can affect the amount and rate of nicotine delivered to the user" (FDA). It goes on to say that it evaluated the nicotine exposure associated with each of the products authorized that day "based on its individual characteristics and as part of the product's overall public health assessment" (FDA).

That framing is what makes the highest-strength product in the set the interesting one. The agency applied the same individual-characteristics assessment to it, and its evaluation found that the new products, "including the 11 mg product authorized today, contain lower levels of most harmful and potentially harmful constituents (HPHCs) when compared to other oral and smokeless tobacco products, many of which were too low to be quantified in the new products" (FDA).

Read that finding precisely, because it is comparative and nothing more. It says these products carry lower levels of most HPHCs than other oral and smokeless tobacco products (FDA). It is not a statement that they are safe, and it does not transfer to any other product.

What it does establish is where the supporting evidence had to come from. Design, formulation and materials are not marketing decisions. They are specifications, and the parts of them that concern the nicotine itself get decided when a buyer selects an ingredient and agrees what it will contain.

Where Formulation and Materials Live in the Application

The PMTA content rule is specific about this. For ingredients other than tobacco, 21 CFR 1114.7(i)(1)(iii) requires the IUPAC chemical name and common name, the Chemical Abstracts Service (CAS) number or FDA Unique Ingredient Identifier (UNII), the function of the ingredient, the quantity reported as mass per portion for portioned products with ranges or means and acceptance limits, and the specification "including purity or grade and supplier" (21 CFR 1114.7).

Those last four words deserve a moment. The supplier is not background information that stays in a procurement folder. It is a required element of the ingredient specification in the application itself (21 CFR 1114.7).

The same paragraph adds a requirement that catches blended and diluted inputs: "For complex purchased ingredients, each single chemical substance reported separately" (21 CFR 1114.7). Something bought as one commercial item does not necessarily enter the file as one line. Materials carry a parallel obligation, with specifications "including quality/grades and suppliers" (21 CFR 1114.7).

What the full ingredient documentation package looks like is covered in what the first authorized pouches revealed about PMTA ingredient documentation. The point here is narrower. FDA said exposure turns on formulation and materials, and the rule then asks the applicant to name, quantify, grade and attribute every one of them.

Constituent Data Is Only as Good as the Laboratory Record

Constituent reporting, HPHCs included, is where the exposure reasoning meets actual numbers. 21 CFR 1114.7(i)(1)(v) sets out what has to travel with those numbers: the mean quantity and variance with unit of measure, the number of samples and measurement replicates for each sample, and a description of method procedure, method validation information and the rationale for selecting each test method (21 CFR 1114.7).

It also requires the name and location of the testing laboratory together with "documentation showing that the laboratory or laboratories is (or are) accredited by a nationally or internationally recognized external accreditation organization" (21 CFR 1114.7). And it asks for two pieces of context that a routine release document has no particular reason to carry: the length of time between the dates of manufacture and the dates of testing, and the storage conditions of the product before it was tested (21 CFR 1114.7).

Set that list against the certificate of analysis you currently receive. A result, a specification range and a pass mark answer the purchasing question. Whether the same document answers the regulatory one depends on what else it carries, and that is worth checking item by item before an order rather than during a deficiency response. The related question of what a stated grade actually guarantees is covered in what USP and EP grade nicotine means.

Nicotine Pouches Have No Design Parameter Table

The rule requires all final design parameters of the product, "specifying nominal values or the explicit range of values as well as the design tolerance (where appropriate)", and where a listed parameter does not apply, applicants "must explain why the required design parameter does not apply or how an alternative design parameter would satisfy the required design parameter" (21 CFR 1114.7).

That paragraph supplies tables of required design parameters by product category. They run from cigarettes through roll-your-own components, cigars and cigar tobacco, waterpipe products, pipes and pipe tobacco, ENDS, e-liquids and heated tobacco products (21 CFR 1114.7). None of them is a nicotine pouch table.

So the characterization argument for a pouch is built rather than filled in. The applicant proposes what the relevant design parameters are, substantiates them, and then has to defend that choice. FDA's statement that exposure depends on design, formulation and materials and the absence of a prescribed parameter list for this format point in the same direction: the burden of describing the product sits with the applicant, and part of that description is the behavior of an ingredient somebody else made.

Authorization Does Not Close the File

A marketing granted order authorizes a specific product as described in the application, and the regulation is explicit about what happens when that product changes. Before introducing a product that results from a modification, an applicant must submit a new PMTA or a supplemental PMTA and obtain a marketing granted order (21 CFR 1114.39). Modification is defined broadly, and includes a change in design, any component, any part or any constituent, or in the content, delivery or form of nicotine, or any other additive or ingredient (21 CFR 1114.3).

Short of that threshold, a reporting obligation runs for the life of the order. A periodic report is due within 60 calendar days of the reporting dates specified in the order, and it must contain a description of all changes made to the manufacturing, facilities or controls during the reporting period, together with a comparison of each change to what was described in the PMTA, the rationale for making it, and the basis for concluding that it does not result in a new tobacco product outside the scope of the order (21 CFR 1114.41).

Those two requirements land on the supplier relationship whether or not anyone plans for it. A change to specification, process or manufacturing site upstream becomes something the order holder has to characterize and justify downstream. Learning about it from a shifted result on an incoming certificate is a poor position from which to write that justification.

Record retention closes the loop, and it names the third party directly. Records related to and including the PMTA must be retained for at least 4 years from the date the marketing granted order is issued (21 CFR 1114.45), and the applicant must ensure those records remain readily available to the agency on request, including where records are maintained by a third party on the applicant's behalf (21 CFR 1114.45). Records a supplier holds are still the applicant's responsibility.

What This Means for a Nicotine Buyer

None of this requires guessing at what the agency wants. Every item below comes from a requirement quoted above.

1. The purity or grade specification and the supplier identity that will appear in the ingredient specification (21 CFR 1114.7).
2. The CAS number or UNII, and the quantity expressed as mass per portion with ranges or means and acceptance limits rather than a nominal figure (21 CFR 1114.7).
3. For a dilution, a salt or any other complex purchased input, a composition broken out far enough that each single chemical substance can be reported separately (21 CFR 1114.7).
4. A certificate of analysis carrying the test method, method validation information, the laboratory's identity and evidence of its accreditation, the interval between manufacture and testing, and the storage conditions before testing (21 CFR 1114.7).
5. A written commitment to notify before any change to specification, process or manufacturing site, because that change becomes a described and justified line in a periodic report (21 CFR 1114.41).
6. Confirmation that supporting records stay available for the retention period, given that the applicant remains answerable for records a third party holds (21 CFR 1114.45).

The questions are the same whether the nicotine is a salt intended for a pouch format or a pharmacopoeial grade base. Form-specific considerations are covered on our nicotine salts page and in how your nicotine source affects FDA submissions, and the origin and chain-of-custody layer underneath all of it in nicotine traceability from seed to shipment.

The practical next step is a documentation conversation rather than a purchase order. Our technical documents library lists specifications, methods of analysis, safety data and certificates of analysis by product and document type, and if any of the six items above is unclear for the material you buy today, that is the gap worth closing first.

Frequently Asked Questions